The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study

Psychoneuroendocrinology

Volumn 51, Issue , 2015, Pages 585-588

  Jetly, Rakesh ^a   Heber, Alexandra ^a   Fraser, George ^b   Boisvert, Denis ^b  

^a Canadian Forces Health Services Group Headquarters   (Canada)

^b Canadian Forces Health Services   (Canada)

Author keywords

Nabilone; Nightmares; PTSD; RCT; Treatment

Indexed keywords

NABILONE; PLACEBO; ANXIOLYTIC AGENT; DRONABINOL;

ADULT; AGED; ARTICLE; CANADIAN; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION OF CHANGE; CLINICIAN ADMINISTERED PTSD SCALE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; GENERAL WELL BEING QUESTIONNAIRE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; NIGHTMARE; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRING AND DISTRESSING DREAM SCORE; SCORING SYSTEM; SOLDIER; XEROSTOMIA; ANALOGS AND DERIVATIVES; CANADA; DREAM; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

ADULT; ANTI-ANXIETY AGENTS; CANADA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DREAMS; DRONABINOL; HUMANS; MALE; MIDDLE AGED; MILITARY PERSONNEL; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 84920602691     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.11.002     Document Type: Article

References (13)

1. Aurora R.N., Zak R.S., Auerbach S.H., Casey K.R., Chowduri S., Karippot A., Maganti R.K., Ramar K., Kristo D.A., Bista S.R., Lamm C.I., Morgenthaler T.I. Best practice guide for the treatment of nightmare disorder in adults. J. Clin. Sleep Med. 2010, 6(4):389-401.
2. Cameron C., Watson D., Robinson J. Use of a synthetic cannabinoid in a correctional population for PTSD related insomnia and nightmares, chronic pain, harm reduction and other indications: a retrospective evaluation. J. Clin. Psychopharmacol. 2014, 34:559-564.
3. Fraser A.D., Meatherall R. Lack of interference by nabilone in the EMIT d.a.u. cannabinoid assay, Abbott TDx cannabinoid assay, and a sensitive TLC assay for delta 9-THC-carboxilic acid. J. Anal. Toxicol. 1989, 13:240.
4. Fraser G.A. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci. Ther. 2009, 15:84-88.
5. Friedman M.J. Toward rational pharmacotherapy for posttraumatic stress disorder: reprise. Am. J. Psychiatry 2013, 170:944-946.
6. Gehrman P.R., Harb G.C. Treatment of nightmares in the context of posttraumatic stress disorder. J. Clin. Psychol. 2010, 66:1185-1194.
7. Maher M.J., Rego S.A., Asnis G.M. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 2006, 20:567-590.
8. Nappi C.M., Drummond S.P.A., Hall J.M.H. Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. Neuropharmacology 2012, 62:576-585.
9. Neumeister A., Normandin M.D., Pietrzak R.H., Piomelli D., Zheng M.Q., Gujarr0_Anton A., Potenza M.N., Bailey C.R., Lin S.F., Najafzadeh S., Ropchan J., Henry S., Corsi-Travali S., Carson S.E., Huang Y. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry 2013, 18:6-13.
10. Raskind M.A., Peterson K., Williams T., Hoff D.J., Hart K., Holmes H., Homas D., Hill J., Daniels C., Calohan J., Millard S.P., Rohde K., O'Connell J., Pritzl D., Feiszli K., Petrie E.C., Gross C., Mayer C.L., Freed M.C., Engel C., Peskind E.R. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am. J. Psychiatry 2013, 170:1003-1010.
11. Ware M.A., St-Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010, 105:494-503.
12. Wissel J., Haydn T., Müller J., Schelosky L.D., Brenneis C., Berger T., Poewe W. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J. Neurol. 2006, 253:1337-1341.
13. Wittmann L., Schredl M., Kramer M. Dreaming in posttraumatic stress disorder: a critical review of phenomenology, psychophysiology and treatment. Psychother. Psychosom. 2007, 76:25-39.